Pfizer, Samsung Research Group Details Second Gene Fusion Assay on Nanostring Platform | GenomeWeb

A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.

According to the group — which published a description of the method and its performance in the Journal of Molecular Diagnostics this month — the multi-fusion assay shows promise "as a more practical and cost-effective screening modality for detecting rare but targetable fusions in NSCLC."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.